Evidence map›Paper›PMID 41087176›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Chinese expert consensus on the diagnosis and treatment of plasma cell leukemia (2025)].

Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO), Myeloma & Plasma Cell Disease Group, Hematology Oncology Committee of China Anti-Cancer Association (CACA), Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association

Abstract readEnglish AbstractConsensus Statement
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO)
Myeloma & Plasma Cell Disease Group, Hematology Oncology Committee of China Anti-Cancer Association (CACA)
Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma cell leukemia (PCL) is a rare and highly aggressive form of plasma cell dyscrasia, distinguished by its rapid clinical course and dismal prognosis. This guideline is intended to offer clinicians evidence-based, comprehensive recommendations encompassing diagnostic criteria, risk stratification, therapeutic approaches-including frontline treatment, hematopoietic stem cell transplantation, and the incorporation of novel therapeutic agents-as well as protocols for long-term follow-up. The overarching objective is to promote standardized clinical management and ultimately enhance both survival outcomes and quality of life for patients diagnosed with PCL.

Indexed as

Leukemia, Plasma CellChinaConsensusEast Asian PeopleHematopoietic Stem Cell TransplantationHumansPrognosisQuality of Life

Identifiers

PMID41087176
PMCPMC12541478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.